Atrial fibrillation in cancer patients treated with BTK inhibitors
Official title: Atrial Fibrillation Among Patients with Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy
Funded at Stanford University · NIH-11296763 · Data updated 2026-11-12
This project looks at how often and how badly atrial fibrillation happens in people with blood cancers who are taking Bruton’s tyrosine kinase inhibitors, and how to predict and manage it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | July 1, 2026 |
| Project end | March 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $743,696 |
| NIH project number | 1R01HL179128-01A1 |
| Project ID | NIH-11296763 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with hematologic malignancies being treated with BTK inhibitors who are at risk for arrhythmias.
✕Less likely to help
Patients not on BTK inhibitors or without a history or risk of atrial fibrillation may not directly benefit.
What this research studies
For people with blood cancers on BTK inhibitors, this study aims to understand the true burden of atrial fibrillation beyond what is seen in initial trials. It will use more comprehensive heart-monitoring and data analysis to capture asymptomatic and intermittent AF episodes, how long patients spend in AF, and related risks. The researchers will develop BTKI-specific risk scores to better predict who is at higher risk for AF and its complications. The ultimate goal is to inform better monitoring, prevention, and treatment decisions so patients can stay on cancer therapy safely. This work could lead to personalized care plans that reduce interruptions in cancer treatment and improve overall outcomes.
Why it matters
Potential benefit: Patients could receive more precise AF risk assessment and tailored management to minimize treatment interruptions and complications.
How similar studies have gone: Previous studies have reported AF incidence in BTKI-treated patients but lacked comprehensive, prospective AF burden assessment and BTKI-specific risk tools.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Baykaner, Tina — Stanford University
- Study coordinator: Baykaner, Tina
Related research
Other NIH-funded projects on the same topics.
-
Adapting flow cytometry to detect childhood leukemias in Kenya using a single-test screen
A low-cost, blood-based flow cytometry screen in Kenya aims to detect and triage suspected leukemias in children and young adults.
-
Cardiomyocyte-fibroblast signaling in atrial fibrillation
A researcher at Baylor College of Medicine is studying how signals between heart muscle cells and supportive heart cells influence atrial fibrillation, with the goal of finding new ways to prevent or treat this common heart rhythm problem.
-
Understanding why patients with blood cancers start and stick with oral cancer medicines
A study to learn what helps or hinders Black patients with blood cancers in starting and continuing their prescribed oral cancer medicines.
-
Anticoagulation in ICH Survivors with Atrial Fibrillation and Small Vessel Disease
This project looks at how to safely use blood-thinning medicines in people who survived a brain bleed and also have atrial fibrillation and small vessel disease.
-
Lowering heart inflammation to reduce atrial fibrillation risk in people with diabetes
Seeing whether blocking a pro-inflammatory enzyme or boosting the heart's natural inflammation-resolving signals can lower atrial fibrillation risk in people with diabetes.
-
Why some blood cancer cells survive after treatment by resisting natural killer cells
This work is trying to understand why leftover blood cancer cells in leukemia and multiple myeloma survive treatment by escaping natural killer immune cells.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.